Emerging company was identified as the ‘Charter Supporter” of this emerging Patient Organization, building trust and demonstrating corporate leadership in this defined patient area where they are in R&D.
Company has two-way dialogue with Organization leadership and patients who provide input and perspectives on a variety of corporate activities
Company garners insights and participation with natural history study, gaining a better understanding of the condition
Insights from Patient Organization and patients themselves inform the corporate strategy and identity of this emerging life sciences company as they progress through the clinical stages of drug development.
